Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Immunol Methods. 2018 Aug 23;462:59–64. doi: 10.1016/j.jim.2018.08.010

Table 1.

Patient characteristics for validation study.

Disease Diagnosis HCC1 Cirrhosis2 p Value3
Number 75 75
Etiology% (HBV/HCV/other) 4 100/0/10 100/0/0
Age (mean, SD) 5 54.1 (11.7) 47.8 (11.9) 0.0005
AFP ng/mL (mean, SD) 6 842.7 (1291) 5.2 (9.2) <0.0001
AST IU/mL (mean, SD) 7 50.9 (65.4) 30.5 (21.6) 0.0003
ALK IU/mL (mean, SD) 8 126.2(113.7) 69.2 21.1) <0.0001
Gender(M:F)% 9 80/20 48/52 <0.0001
Tumor Stage (1/2/3/4/unk)%10 3/24/25/8/40 N/A
1&2)

Disease diagnosis was determined by MRI (HCC) or by liver biopsy (in the case of cirrhosis). All HCC patients had cancer in the background of cirrhosis.

3)

P value comparing two groups. Patient’s characteristics were analyzed through the use of ChiSquare test, Fisher’s exact test or Welch’s approximate t test as appropriate. All test were two-sided, and p<0.05 was considered significant.

4)

For Etiology: HBV, hepatitis B virus; HCV, hepatitis C virus; other, liver disease consisting of cryptogenic liver disease or alcohol induced liver disease.

5)

Mean age of groups.

6)

Mean level of AFP.

7)

Mean level of aspartate aminotransferase (AST) with the standard deviation indicated (in U/L).

8)

Mean level of alkaline phosphatase with the range indicated (in U/L).

9)

Gender as a % male or female.

10)

Tumor staging information. Unknown indicates patients with unknown tumor stage.